Cancer of the Prostate: Clinical Trials

15 trials for Cancer of the Prostate, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 2 terminated, 1 withdrawn. 15 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 215Completed 12, Terminated 2, Withdrawn 1
Phase 12Completed 1, Withdrawn 1

Follow Cancer of the Prostate: new trials by email Literature Review of Cancer of the Prostate trials Research Report on Cancer of the Prostate

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
NUV-422, Enzalutamide - Prostate Cancer, Prostatic Cancer
Phase 1 / Phase 2WithdrawnNuvation Bio Inc.2022-09-012022-08-05
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
I-131-1095, Enzalutamide - Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
Phase 2CompletedProgenics Pharmaceuticals, Inc.1202019-05-302025-10-14
A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer
177Lu-PSMA617, Cabazitaxel - Cancer of the Prostate, Metastatic Cancer
Phase 2CompletedAustralian and New Zealand Urogenital and Prostate Cancer Trials Group2012018-01-292022-06-13
Prostate Cancer Survivors and Exercise and Behavioral Counseling
Supervised Physical Activity Plus Behavioral Counseling, Supervised Physical Activity Plus Exercise Counseling - Physical Activity, Cancer of the Prostate
Phase 2CompletedUniversity of Illinois at Urbana-Champaign272017-07-062019-12-20
Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer
Apalutamide - Cancer of the Prostate
Phase 2CompletedSingapore General Hospital302017-06-202020-03-19
Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone
Enzalutamide, Metformin - Cancer of the Prostate, Prostate Cancer
Phase 2TerminatedSwiss Cancer Institute1692016-06-102023-06-27
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
BHR-200 (0.36% transdermal 17β-estradiol gel), Placebo - Cancer of the Prostate
Phase 2TerminatedBHR Pharma, LLC342015-07-012022-03-31
Sipuleucel-T Manufacturing Demonstration Study
sipuleucel-T - Cancer of Prostate, Cancer of the Prostate
Phase 2CompletedDendreon472012-06-012015-12-09
Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
androgen ablation (AA), DC1 vaccine - Cancer of Prostate, Cancer of the Prostate
Phase 2CompletedRoswell Park Cancer Institute132009-09-012020-11-03
Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer
Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E, Placebo - Cancer of the Prostate, Prostate Cancer
Phase 2CompletedUniversity Health Network, Toronto482008-10-012017-10-26
Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance
Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E, Placebo - Cancer of the Prostate, Prostate Cancer
Phase 2CompletedUniversity Health Network, Toronto162008-05-012018-02-14
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
IPI-504 - Prostate Cancer, Prostatic Neoplasms
Phase 2CompletedInfinity Pharmaceuticals, Inc.192007-11-012012-12-11
Vessel Sparing Prostate Radiation Therapy
Radiation Therapy - Cancer of the PROSTATE
Phase 2CompletedUniversity of Michigan Rogel Cancer Center1352004-11-012018-03-05
Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer
Dendritic cell application - Cancer of the Prostate
Phase 1 / Phase 2CompletedCantonal Hospital of St. Gallen152002-11-012015-08-17
A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy
YM155 - Prostate Cancer, Cancer of Prostate
Phase 2CompletedAstellas Pharma Inc2012-06-07

Narrower conditions

Prostatic Neoplasms (15)  ·  Male Urogenital Diseases (2)  ·  Cognitive Dysfunction (1)  ·  Motor Activity (1)  ·  Neoplasm Metastasis (1)  ·  Prostatic Neoplasms, Castration-Resistant (1)

Broader conditions

Genital Diseases (15)  ·  Genital Diseases, Male (15)  ·  Genital Neoplasms, Male (15)  ·  Neoplasms (15)  ·  Neoplasms by Site (15)  ·  Prostatic Diseases (15)  ·  Urogenital Diseases (15)  ·  Urogenital Neoplasms (15)  ·  Male Urogenital Diseases (13)  ·  Behavior (1)  ·  Cognition Disorders (1)  ·  Mental Disorders (1)  ·  Neoplastic Processes (1)  ·  Neurocognitive Disorders (1)  ·  Pathologic Processes (1)

Interventions

enzalutamide (3)  ·  Cholecalciferol (2)  ·  Lycopene (2)  ·  Selenium (2)  ·  Tea (2)  ·  Vitamin E (2)  ·  Behavior Therapy (1)  ·  Metformin (1)  ·  Pluvicto (1)  ·  Radiotherapy (1)  ·  apalutamide (1)  ·  cabazitaxel (1)  ·  sepantronium (1)  ·  sipuleucel-T (1)  ·  tanespimycin (1)

Sponsors

University Health Network, Toronto (2)  ·  Astellas Pharma Inc (1)  ·  Australian and New Zealand Urogenital and Prostate Cancer Trials Group (1)  ·  BHR Pharma, LLC (1)  ·  Cantonal Hospital of St. Gallen (1)  ·  Dendreon (1)  ·  Infinity Pharmaceuticals, Inc. (1)  ·  Nuvation Bio Inc. (1)  ·  Progenics Pharmaceuticals, Inc. (1)  ·  Roswell Park Cancer Institute (1)  ·  Singapore General Hospital (1)  ·  Swiss Cancer Institute (1)  ·  University of Illinois at Urbana-Champaign (1)  ·  University of Michigan Rogel Cancer Center (1)

Countries

United States (8)  ·  Canada (3)  ·  Netherlands (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Austria (1)  ·  France (1)  ·  Singapore (1)  ·  Switzerland (1)

Top investigators

Neil Fleshner (2)  ·  Andrew Stubbs, PhD (1)  ·  Art F Kramer, PhD (1)  ·  Christian Rothermundt, MD (1)  ·  D. Buell, MD (1)  ·  Daniel Spratt, MD (1)  ·  Edward McAuley, PhD (1)  ·  Jean-Claude Provost, MD (1)  ·  Kendrith M Rowland, MD (1)  ·  Leonard J Appleman, MD, PhD (1)  ·  Linda Trinh, PhD (1)  ·  Lui Shiong Lee, MBBS,MRCS (1)  ·  Michael Hofman, A/Prof (1)  ·  Thomas Cerny, Prof. Dr. (1)

Results publications

PMID 28233591, PMID 31595044, PMID 32979134, PMID 33581798, PMID 34373282, PMID 35091711, PMID 36000794, PMID 36261050, PMID 36350899, PMID 38043558, PMID 40425844